利用血浆游离DNA片段组学超灵敏且经济地检测原发性肝癌
本研究基于血浆游离DNA片段组学特征,利用全基因组测序数据构建集成堆叠模型,用于原发性肝癌(含肝细胞癌、肝内胆管癌及混合型)的早期检测及区分肝内胆管癌与肝细胞癌。训练队列纳入192例原发性肝癌患者和170例非癌对照,独立测试队列纳入189例患者和164例对照。模型在测试队列中检测癌症的AUC为0.995,98.8%特异性下灵敏度为96.8%,在低覆盖度(1X)数据下仍保持良好性能。
要点
- 模型检测原发性肝癌的AUC为0.995,98.8%特异性下灵敏度为96.8%。
- 早期(I期)灵敏度95.9%,II期97.9%,小肿瘤(≤3 cm)98.2%。
- 区分肝内胆管癌与肝细胞癌的独立模型AUC为0.776。
核心结论
- 该模型仅使用低覆盖度全基因组测序数据,以较低成本实现了优于既往报道的性能,在原发性肝癌及其亚型的超灵敏、经济检测方面展现出优异的临床潜力。
研究设计与样本
- 研究纳入训练队列192例原发性肝癌患者(159例肝细胞癌、26例肝内胆管癌、7例混合型)和170例非癌对照(包括53例肝硬化或HBV阳性),以及独立测试队列189例患者(157例肝细胞癌、26例肝内胆管癌、6例混合型)和164例非癌对照(包括51例肝硬化或HBV阳性),利用血浆游离DNA进行全基因组测序并构建集成堆叠模型。
主要发现
- 测试队列中模型检测癌症的AUC为0.995,98.8%特异性下灵敏度为96.8%。
- 模型检测早期原发性肝癌的灵敏度:I期95.9%,II期97.9%;小肿瘤(≤3 cm)灵敏度98.2%。
- 模型检测肝细胞癌的灵敏度为96.2%,检测肝内胆管癌的灵敏度为100%。
- 区分原发性肝癌与肝硬化或HBV的AUC为0.985(原文写作96.8%特异性下96.1%特异性,此处表述有矛盾)。
- 在降采样过程中,即使使用1X覆盖度数据,模型仍保持一致的性能(AUC为0.994,98.8%特异性下灵敏度为93.7%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Early detection of primary liver cancer (PLC), including HCC, intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC (cHCC-ICC), is essential for patients' survival. This study aims to develop an accurate and affordable method for PLC early detection and differentiating ICC from HCC using plasma cell-free DNA (cfDNA) fragmentomic profiles. APPROACH AND RESULTS: Whole-genome sequencings (WGS) were performed using plasma cfDNA samples from 192 patients with PLC (159 HCC, 26 ICC, 7 cHCC-ICC) and 170 noncancer controls (including 53 liver cirrhosis [LC] or HBV-positive) enrolled in the training cohort. An ensembled stacked model for PLC detection was constructed using the training cohort. The model performance was assessed in an independent test cohort (189 patients with PLC [157 HCC, 26 ICC, 6 cHCC-ICC], 164 noncancer controls [including 51 LC/HBV]). Our model showed excellent performance for cancer detection in the test cohort (AUC: 0.995, 96.8% sensitivity at 98.8% specificity). It showed excellent sensitivities in detecting early-stage PLC (I: 95.9%, II: 97.9%), small tumors (≤3 cm: 98.2%), and HCC (96.2%) or ICC (100%). The AUC for distinguishing PLC from LC/HBV reached 0.985 (96.8% specificity at 96.1% specificity). Promisingly, our model maintained consistent performances during the downsampling process, even using 1X coverage data (AUC: 0.994, 93.7% sensitivity at 98.8% specificity). A separate model showed potential for distinguishing ICC from HCC (AUC: 0.776). CONCLUSIONS: Our model, outperforming previous reports at a lower cost by solely using low-coverage WGS data, exhibits excellent clinical potential for ultrasensitive and affordable detection of PLC and its subtypes.
引用
- Zhang X, Wang Z, Tang W, et al. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology. 2022. PMID: 34954829. doi:10.1002/hep.32308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。